Stanniocalcin-1 as a Novel Marker to Detect Minimal Residual Disease of Human Leukemia

Access this Article

Search this Article

Author(s)

    • TOHMIYA YASUO
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • KOIDE YOSHIO
    • Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
    • FUJIMAKI SHINICHI
    • Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
    • HARIGAE HIDEO
    • Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
    • FUNATO TADAO
    • Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
    • KAKU MITSUO
    • Department of Molecular Diagnostics, Tohoku University Graduate School of Medicine
    • ISHII TOMONORI
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • MUNAKATA YASUHIKO
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • KAMEOKA JUNICHI
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine
    • SASAKI TAKESHI
    • Department of Rheumatology and Hematology, Tohoku University Graduate School of Medicine

Abstract

Stanniocalcin is a glycoprotein hormone that regulates the calcium level in fish. We found that mRNA of human stanniocalcin 1 (STC-1) is detectable in phytohemagglutinin-stimulated T cells and in most human leukemia cell lines, suggesting a role of STC-1 for cell proliferation. This finding prompts us to study the usefulness of STC-1 for monitoring acute leukemia. The levels of STC-1 transcripts increased in patients with acute leukemia at diagnosis and relapse, as judged by quantitative real-time RT-PCR. Levels of transcripts rapidly decreased to within the cut-off levels, when the blast numbers decreased with chemotherapy. Prolonged elevation of STC-1 levels after treatment was associated with a poor prognosis. All of 7 patients relapsed 1 to 4 months after they showed an elevated level of the transcripts in clinical remission. These results indicate that STC-1 is a novel marker for minimal residual disease of acute leukemia, and for an early diagnosis of relapse.

Journal

  • The Tohoku Journal of Experimental Medicine

    The Tohoku Journal of Experimental Medicine 204(2), 125-133, 2004-10-01

    Tohoku University Medical Press

References:  22

Cited by:  2

Codes

  • NII Article ID (NAID)
    10013562947
  • NII NACSIS-CAT ID (NCID)
    AA00863920
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    00408727
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top